NasdaqGS:KURA

Stock Analysis Report

Executive Summary

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has Kura Oncology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KURA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

23.9%

KURA

4.7%

US Biotechs

9.9%

US Market


1 Year Return

-42.5%

KURA

-0.4%

US Biotechs

-11.9%

US Market

Return vs Industry: KURA underperformed the US Biotechs industry which returned 0% over the past year.

Return vs Market: KURA underperformed the US Market which returned -11.5% over the past year.


Shareholder returns

KURAIndustryMarket
7 Day23.9%4.7%9.9%
30 Day-21.3%-6.7%-15.0%
90 Day-33.0%-8.6%-21.5%
1 Year-42.5%-42.5%0.4%-0.4%-10.0%-11.9%
3 Year8.4%8.4%9.3%6.6%12.3%5.1%
5 Yearn/a-6.4%-10.6%32.5%18.1%

Price Volatility Vs. Market

How volatile is Kura Oncology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Kura Oncology undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: KURA ($9.54) is trading below our estimate of fair value ($79.17)

Significantly Below Fair Value: KURA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: KURA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: KURA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KURA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KURA is good value based on its PB Ratio (2x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Kura Oncology forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

39.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KURA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KURA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KURA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if KURA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if KURA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: KURA is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Kura Oncology performed over the past 5 years?

-28.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KURA is currently unprofitable.

Growing Profit Margin: KURA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KURA is unprofitable, and losses have increased over the past 5 years at a rate of -28.8% per year.

Accelerating Growth: Unable to compare KURA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KURA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: KURA has a negative Return on Equity (-28.86%), as it is currently unprofitable.


Next Steps

Financial Health

How is Kura Oncology's financial position?


Financial Position Analysis

Short Term Liabilities: KURA's short term assets ($239.6M) exceed its short term liabilities ($15.6M).

Long Term Liabilities: KURA's short term assets ($239.6M) exceed its long term liabilities ($7.6M).


Debt to Equity History and Analysis

Debt Level: KURA's debt to equity ratio (3.4%) is considered satisfactory.

Reducing Debt: KURA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: KURA has a low level of unsold assets or inventory.

Debt Coverage by Assets: KURA's debt is covered by short term assets (assets are 32x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KURA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if KURA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Kura Oncology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KURA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate KURA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KURA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KURA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KURA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Troy Wilson (50yo)

5s

Tenure

US$4,745,838

Compensation

Dr. Troy Edward Wilson, Ph.D., J.D. has been the Chairman of the Board, Chief Executive Officer and President at Kura Oncology, Inc. since March 2015. He was the Chief Financial Officer and Principal Accou ...


CEO Compensation Analysis

Compensation vs Market: Troy's total compensation ($USD4.75M) is above average for companies of similar size in the US market ($USD2.14M).

Compensation vs Earnings: Troy's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Troy Wilson
Chairman5yrsUS$4.75m4.01% $17.4m
Marc Grasso
CFO & Chief Business Officer1.58yrsUS$3.63mno data
Antonio Gualberto
0.083yrUS$2.02m0.75% $3.2m
Kathleen Ford
Chief Operating Officer0.58yrno datano data
Pete De Spain
Vice President of Investor Relations & Corporate Communicationsno datano datano data
James Basta
Chief Legal Officer0.33yrno datano data
Bridget Martell
Acting Chief Medical Officer0.083yrno datano data
Kirsten Flowers
Chief Commercial Officer0.17yrno datano data

0.3yrs

Average Tenure

51.5yo

Average Age

Experienced Management: KURA's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Troy Wilson
Chairman5yrsUS$4.75m4.01% $17.4m
Robert Hoffman
Independent Director5yrsUS$200.72k0.021% $90.6k
Thomas Malley
Independent Director4.42yrsUS$191.97kno data
Faheem Hasnain
Independent Director4.92yrsUS$194.47k0.053% $228.8k
Frank McCormick
Scientific Advisorno datano datano data
Neal Rosen
Scientific Advisorno datano datano data
Kevan Shokat
Chairman of the Scientific Advisory Boardno datano datano data
Alan Houghton
Clinical Advisorno datano datano data
Steven Stein
Independent Director3.17yrsUS$185.72kno data
Azra Raza
Clinical Advisorno datano datano data

4.9yrs

Average Tenure

53yo

Average Age

Experienced Board: KURA's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.2%.


Top Shareholders

Company Information

Kura Oncology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kura Oncology, Inc.
  • Ticker: KURA
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$433.384m
  • Shares outstanding: 45.43m
  • Website: https://www.kuraoncology.com

Number of Employees


Location

  • Kura Oncology, Inc.
  • 3033 Science Park Road
  • Suite 220
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KURANasdaqGS (Nasdaq Global Select)YesNew Common StockUSUSDSep 2015
KURDB (Deutsche Boerse AG)YesNew Common StockDEEURSep 2015

Biography

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company’s lead product candidate is tipifarnib, an oral farnesyl transferase inhibitor for the treatment of head and neck squamous cell carcinoma, chronic myelomonocytic leukemia, pancreatic cancer, and other squamous cell carcinomas, as well as to treat adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma, follicular T-cell lymphoma, and peripheral T-cell lymphoma with T follicular helper phenotype. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. The company was founded in 2014 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/28 02:29
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.